SCHEMBL19185282

SCHEMBL19185282

CC(C)Cc1cnc2ccccn12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GGPS1 O95749 1/20 0.49
FDPS P14324 1/20 0.49
GPR84 Q9NQS5 1/20 0.46
DRD4 P21917 1/20 0.44
DRD3 P35462 1/20 0.44
NPSR1 Q6W5P4 2/20 0.42
FLT3 P36888 1/20 0.41
ADORA3 P0DMS8 1/20 0.40
DYRK1A Q13627 1/20 0.39
MIF P14174 1/20 0.39
KDM4E B2RXH2 3/20 0.38
LMNA P02545 1/20 0.38
PKM P14618 1/20 0.38
PIK3CA P42336 1/20 0.38
ALDH1A1 P00352 3/20 0.37
RAB9A P51151 2/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
PLAU P00749 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25291018 0.87 GGPS1 (0.47) GGPS1FDPSGPR84DRD4DRD3
SCHEMBL25293278 0.84 GGPS1 (0.45) GGPS1FDPSGPR84DRD4DRD3
SCHEMBL25245613 0.82 GGPS1 (0.46) GGPS1FDPSGPR84DRD4DRD3
SCHEMBL8360107 0.80 GGPS1 (0.53) GGPS1FDPSGPR84DRD4DRD3
SCHEMBL20439096 0.80 GGPS1 (0.50) GGPS1FDPSGPR84DRD4DRD3
SCHEMBL21527429 0.80 GGPS1 (0.47) GGPS1FDPSGPR84DRD4DRD3
SCHEMBL12801878 0.77 GGPS1 (0.50) GGPS1FDPSGPR84DRD4DRD3
SCHEMBL9797098 0.77 GGPS1 (0.56) GGPS1FDPSGPR84DRD4DRD3
SCHEMBL18265799 0.77 GGPS1 (0.53) GGPS1FDPSGPR84DRD4DRD3
SCHEMBL2017760 0.77 GGPS1 (0.53) GGPS1FDPSGPR84DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230263749-A1 COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS CURASEN THERAPEUTICS, INC. 2023-08-24 US disclosed
US-20230157974-A1 COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS CURASEN THERAPEUTICS, INC. 2023-05-25 US disclosed
US-20220213069-A1 ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 VANDERBILT UNIVERSITY 2022-07-07 US disclosed
US-9920075-B2 Triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase BRISTOL-MYERS SQUIBB COMPANY (US) 2018-03-20 US disclosed
US-20170280720-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-10-05 US disclosed
US-20170280720-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-10-05 US disclosed
US-20170247396-A1 TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE BRISTOL MYERS SQUIBB CO (US) 2017-08-31 US disclosed
US-9718816-B2 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as CARM1 inhibitors and uses thereof Epizyme, Inc. (US) 2017-08-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170247396-A1 TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE EPX, MPO, SERPINB1 GGPS1 2251/4885FDPS 1847/4885GPR84 1004/4885
US-20170280720-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 GGPS1 1273/4885FDPS 777/4885GPR84 3351/4885
US-20220213069-A1 ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 CHRM2, CHRM3, CHRM4 GGPS1 1772/4885FDPS 2610/4885GPR84 92/4885
US-20230263749-A1 COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS ADRA2A, SNCA, ADRA1A GGPS1 2576/4885FDPS 4385/4885GPR84 403/4885
US-20230157974-A1 COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS ADRA2A, SNCA, ADRA1A GGPS1 2576/4885FDPS 4385/4885GPR84 403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.